Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind very-low-dose controlled trial of Xiaoer Liuwei Eczema Gel in children with atopic dermatitis
CTR20262867Phase 2Active
- Sponsor
- Shandong Hanfang Pharmaceutical
- Start
- Jul 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Xiaoer Liuwei Eczema Gel in atopic dermatitis (AD) (2 arms), sponsored by Shandong Hanfang Pharmaceutical. Primary endpoints: Change from baseline in EASI score and Change from baseline in IGA score. Started Jul 2026; status: active.
02
Drugs
Xiaoer Liuwei Eczema Gel
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20262867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262867.